This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Kure It Cancer Research
Drs. William Y. Kim, of UNC, and James W. Mier, of Harvard, will each receive $250,000 grants to support innovative, translational kidney cancer research.
Newport Beach, CA (PRWEB) December 28, 2012
The American Association for Cancer Research and Kure It are pleased to announce that William Y. Kim, M.D., and James W. Mier, M.D., will each receive a 2012 AACR-Kure It Grant for Kidney Cancer Research.
Kim, assistant professor in the departments of medicine and genetics at the University of North Carolina School of Medicine, in Chapel Hill, and Mier, associate professor at Harvard Medical School in the division of hematology and oncology at Beth Israel Deaconess Medical Center, in Boston, Mass., will each receive $250,000 during the two-year grant term. In addition, Kim and Mier will be recognized at the Annual Grants Reception and Dinner during the AACR Annual Meeting 2013, to be held April 6-10 in Washington, D.C.
These grants are designed to provide support for innovative translational kidney cancer research designed to improve the survival and quality of life of patients with kidney cancer and, in turn, lead to individualized therapeutic options for the treatment or development of promising new kidney cancer therapies. Kure It partnered with the AACR in early 2012 with the goal of becoming a leading supporter of kidney cancer research. Kure It founder Barry Hoeven recognized the AACR for assembling a team of specialists to review the submitted proposals, as well as their role in making researchers aware of the funds availaible. “The AACR partnership brought us a much larger pool of projects from which to choose, and we were pleased to be able to fund a second award, thanks to consistent funding from our supporters.”
Kim’s project, “Defining the RCC [Renal Cell Carcinoma] Kinome for Target Discovery and Individualized Therapy,” aims to personalize kinase therapy based on the patient’s kidney tumor.
“Despite the fact that kidney cancer has very few activating mutations in kinases, they can be activated through alternate means and remain tenable therapeutic targets in renal cell carcinoma. We will use a novel, quantitative mass spectroscopy-based assay developed at University of North Carolina to assess the global activation state of the kinome and identify both novel as well as currently actionable targets,” said Kim, a faculty member of UNC Lineberger Comprehensive Cancer Center.
Mier’s research will explore the mechanism by which HDM2 antagonists and vascular endothelial growth factor-targeted drugs act together to block tumor angiogenesis and induce disease regression in renal cell carcinomas in his project, “HDM2/HDMX as a Therapeutic Target in Renal Cell Carcinoma.” His work will support the ongoing translational kidney cancer research at Dana-Farber/Harvard Cancer Center.
“I am honored to have been selected for this grant and am grateful to Kure It and the AACR for making the funds available. Everyone in my lab feels encouraged by this award. We are planning to use the funds to carry out preclinical studies of novel agents that may prove useful in patients with RCC. The AACR-Kure It funds will allow us to carry out studies that we might otherwise not have been able to undertake,” said Mier.
The expert scientific review committee, assembled by the AACR, received 44 high-caliber applications from independent investigators who proposed to develop and study new ideas and approaches that will have a direct application and relevance to patients with kidney cancer.
The AACR and Kure It are committed to collaboratively sustain the grant to award funding to the most promising kidney cancer research project.
# # #
About Kure It
Kure It is a non-profit organization whose mission is to raise money for cancer research specialists conducting innovative projects to better treat and ultimately cure kidney cancer and other underfunded malignancies. Kure It has raised over $1.5 million for research since being founded in 2007. Kure It supports research at major institutions, including Samuel Oschin Cancer Center at Cedars Sinai; Beckman Research Institute at the City of Hope; and Knight Research Institute at Oregon Health & Science University.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information, visit http://www.AACR.org.
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10273572.htm